Left Ventricular Thrombus Registry

Observational Registry to Determine the Predictors and Outcomes of Patients at Risk of and Diagnosed With Left Ventricular Thrombus

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06963567

Acronym

LVT Registry

Enrollment

1500

Registered

2025-05-09

Start date

2024-05-17

Completion date

2027-01-31

Last updated

2026-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Left Ventricular Thrombus

Brief summary

Left Ventricular Thrombus (LVT) is a blood clot that can develop in a poorly functioning heart. In around 1 in 6 patients who have had a heart attack or diagnosed with heart failure tend to develop blood clots in their main heart chamber. Having a blot clot in the main heart chamber can lead to serious complications such as stroke. Treatment for blood clots is blood thinning medications, which if taken for a prolonged period of time can result in bleeding which further complicates treatment. We hope to gather information to better understand the factors associated with blood clot formation and management in the lower left chamber of the heart. This understanding will hopefully enable us and others to improve management of this condition in the future and therefore help the wider population. As part of this study, bloods and scan results will be recorded and we will complete a short quality of life questionnaire. When participants come in for routine MRI scan, we may capture additional images for further research analysis. A sample of blood no more than one tablespoon will be collected for research analysis at the same time as routine blood test. This will occur at baseline and at around 6 months. At 12 months we will repeat the quality of life questionnaire and collect final data.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Patients with LV thrombus or; * Patients at risk for developing LV thrombus (e.g severe LV dysfunction, LV aneurysm, MI.

Exclusion criteria

* Age \< 18 years * Unable to consent

Design outcomes

Primary

Measure	Time frame	Description
Composite Result	From baseline to final 12 month follow up (+/- 2 months)	To measure the composite result of major bleeding (BARC \>3), stroke and systemic embolisation, and all-cause mortality

Secondary

Measure	Time frame	Description
CMR prediction of thrombus	From baseline to 6 month follow up (+/- 3 months)	To assess CMR based risk prediction model of recurrence of LV thrombus
Blood Test	From baseline to 6 month follow up (+/- 3 months)	To assess blood test variables in the persistence or recurrence of LV thrombus
Quality of Life Questionnaire	From baseline to final 12 month follow up (+/- 2 months)	Participants quality of life (QoL) will be measured using European Quality of Life-5 Dimensions - 5 levels (EQ-5D-5L) questionnaire at baseline and 12 months

Countries

United Kingdom

Outcome results